The preliminary data showed 20% tumor regression from a phase 1 study of LY3321367 (an anti-TIM-3 antibody) monotherapy or in combination with LY3300054 (an anti-PD-L1 antibody) (49). Here, HAVCR2 is linked to neoplasm.